GeneralConnection.com ➔ Dictionary
Dictionary Search

degrader

Synonyms

Noun

1. debaser

2. person, individual, someone, somebody, mortal, human, soul

Usage
Roche flunks its first-line degrader test | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline
Fledgling French biotech pens $128M deal for Kezar's preclinical protein degrader program - Fierce Biotech
GNI Group Highlights Fibrosis Revenue Upside and Advances Degrader Pipeline via Gyre and Cullgen - TipRanks
A STAT3 degrader demonstrates efficacy in venetoclax resistant acute myeloid leukemia - Nature
A targeted protein degrader that doubles as a cancer vaccine - C&EN
Biohaven Highlights Portfolio Progress, Positive Early Patient Data from Priority Degrader Programs and Anticipated Milestones at the 44th Annual J.P. Morgan Healthcare Conference - PR Newswire
Discovery of a Potent and Selective TEAD Degrader with Durable Degradation Activity - Wiley
Developing a CITK protein degrader using the QuicTPD™ platform - Chemistry World
Buy Rating on Foghorn Therapeutics Driven by Lilly Partnership Catalyst, Advancing Degrader Pipeline, and Strengthened Cash Runway - TipRanks
Discovery of a CNS active GSK3 degrader using orthogonally reactive linker screening - Nature
Astellas makes its KRAS degrader choice | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline
A rapid imaging-based screen for induced-proximity degraders identifies a potent degrader of oncoprotein SKP2 - Nature
A new clinical KRAS degrader | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline
Discovery of a novel small molecule degrader of wild type and mutant estrogen receptors using DNA encoded libraries - Nature
ASCO-GI – Astellas focuses on a degrader-chemo combo | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline
RBM39 degrader invigorates innate immunity to eradicate neuroblastoma despite cancer cell plasticity - Nature
Discovery of KRAS(G12D) selective degrader ASP3082 - Nature
Harnessing artificial intelligence to identify Bufalin as a molecular glue degrader of estrogen receptor alpha - Nature
Degrader Therapy Tests Efficacy Against Advanced Prostate Cancer in Preclinical Studies - Jie Luo - UroToday
ASH 2025 preview – another degrader fight | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline
FTO degrader impairs ribosome biogenesis and protein translation in acute myeloid leukemia - Science | AAAS
Pfizer-backed Triana scores $120M series B to take molecular glue degrader into clinic - Fierce Biotech
Google, Johnson & Johnson back protein degrader start-up - C&EN
Dual degrader shows activity in acute myeloid leukemia models - bioworld.com
Arvinas and Pfizer seek a new home for protein degrader drug - Chemistry World
Nurix trims workforce as pivotal trial for lead BTK degrader kicks off - Fierce Biotech
Orum pulls in $100M to fund degrader-antibody conjugate pipeline - FirstWord Pharma
Transcriptomic and epigenetic profiling of neuroblastoma states in response to RBM39 degrader - Nature
FDA accepts BMS protein degrader for review; Disc rare disease drug rejected - Yahoo Finance
Astellas and Amgen join the pan-KRAS push | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline
NEK7 Degrader MRT-8102 Shows Promise in Preclinical Data - The Clinical Trial Vanguard
BeOne tries to repeat the inhibitor-degrader double | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline
Discovery of an LSD1 PROTAC degrader - PNAS
PAQ Therapeutics Announces Series B Extension, Bringing Total Series B Financing to $77 Million; First Patient Dosed in Phase 1 Trial of PT0511, a Pan-KRAS Degrader - PR Newswire
Arvinas to Present Phase 1 Data for ARV-102, a PROTAC LRRK2 Degrader, in Oral Session at the 2026 International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders - The Manila Times
A selective RPL15 PROTAC degrader enhances anti-PD-1 immunotherapy in a murine melanoma tumor model - Nature
Kymera's Oral STAT6 Degrader KT-621 Shows Biologic-Like Activity in Early Atopic Dermatitis Trial - Patient Care Online
Atopic dermatitis data bolster Kymera's hopes of matching Dupixent's efficacy with oral STAT6 degrader - FirstWord Pharma
KT-621 Shows Strong Phase 1 Results as First-in-Class Oral STAT6 Degrader - Dermatology Times
Boundless Bio’s kinesin degrader gains IND approval - bioworld.com
HealZen announces degrader ADC deal - The Pharmaletter
Eilean Therapeutics Presents First-in-Class MALT1 Degrader TE205 Demonstrating In Vivo Efficacy in Ulcerative Colitis at the 4th International Conference on Microbiology and Immunology - PR Newswire
Origami Therapeutics Announces Global Collaboration with Ipsen to Advance Protein Degrader Program - Yahoo Finance
Vepdegestrant, a PROTAC Estrogen Receptor Degrader, in Advanced Breast Cancer - The New England Journal of Medicine
Aditi Shastri Shares a Study on STAT3 Degrader in Venetoclax-Resistant AML - Oncodaily
Amgen buys protein-degrading startup Dark Blue for up to $840M - BioPharma Dive
Novel BTK Degrader Shows Activity in CLL/SLL Regardless of Mutation Status - CancerNetwork
Sanofi pays $15M for another STAT6 degrader from fruitful Nurix collab - Fierce Biotech
Kymera stock jumps on first clinical data for oral STAT6 degrader - FirstWord Pharma
PD-L1 degraders emerge | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline
Fortitude has faith glue degraders can beat ADC resistance - Fierce Biotech
Ascentage Pharma Announces IND Clearance by the China CDE for BTK Degrader APG-3288 - Yahoo Finance
Accelerating protein degrader discovery with the direct-to-biology workflow - News-Medical
Sanofi, Gilead Deepen Protein Degrader Pipelines in Separate Deals With Kymera - BioSpace
Triana adds $120m to push its glue programme | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline
Astellas’ CRBN-based protein degrader inhibits KRAS G12D tumor growth - bioworld.com
Targeting the “Undruggable”: Emerging Degrader Modalities for Novel Target Identification and Validation - Fierce Pharma
Novartis inks a second degrader-focused deal with Monte Rosa - FirstWord Pharma
Biohaven Highlights Innovation and Advancement Across MoDE and TRAP Degrader Platform at R&D Day, Announcing Positive TRAP Degrader Data Achieving > 80% Sustained Reductions in Galactose-Deficient IgA1 (Gd-IgA1) with Potential First-in-Class - PR Newswire
BeOne Medicines’ BTK degrader gains EMA PRIME designation - Pharmaceutical Technology
Pin Therapeutics Initiates First-Patient Dosing of CK1α Degrader PIN-5018 in Phase 1 Trial - PR Newswire
Solid-Phase Parallel Synthesis of Photocleavable Bifunctional Molecules Enables Efficient Phenotypic Protein Degrader Discovery - Wiley Online Library
Former Genentech leaders’ protein degrader startup nets $107M - Endpoints News
From undruggable to oral therapy: The rise of STAT6 degraders - Labiotech.eu
Pfizer, Arvinas lose interest in commercializing PROTAC inhibitor, leading to layoffs at the biotech - Fierce Biotech
Novartis agrees $5.7bn degrader deal with Monte Rosa - pharmaphorum
Kazia advances nuclear PD-L1 degrader with pre-clinical data - The Pharmaletter
Kymera snags Gilead as new partner, while Sanofi opts for next-gen IRAK4 degrader - FirstWord Pharma
PAQ turns degrader tech toward KRAS, raises $39M with backing from J&J - FirstWord Pharma
Prelude Therapeutics pauses clinical development of SMARCA2 degrader program (PRLD:NASDAQ) - Seeking Alpha
GlycoEra secures $130m for IgG4-targeted protein degrader - Pharmaceutical Technology
A highly selective and orally bioavailable casein kinase 1 alpha degrader through p53 signaling pathway targets B-cell lymphoma cells | Leukemia - Nature
Novel JAK1/2 PROTAC degrader effectively improves IBD - bioworld.com
New CDK12/13 dual degrader for TNBC - bioworld.com
Kymera Soars on Early Protein Degrader Data - BioSpace
Kazia Therapeutics reports data on nuclear PD-L1 degrader NDL-2 - bioworld.com
Kymera Starts Phase 2b Asthma Trial Testing Oral STAT6 Degrader KT-621 - Yahoo Finance
Months after layoffs, AbbVie-partnered protein degrader specialist Plexium raises $60M - Fierce Biotech
Lilly urges degrader caution | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline
Novartis dives deeper into protein degraders with second Monte Rosa deal - BioPharma Dive
Orum Therapeutics Secures Approximately US$100 Million to Accelerate Development of Leading Degrader Antibody Conjugate Programs to Treat Serious Diseases - Business Wire
Exploring CK1 degrader discovery and molecular glue technologies - News-Medical
Kymera suffers Sanofi setback but secures $750M Gilead deal - Fierce Biotech
Kymera's oncology comeback, courtesy of Gilead | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline
Amphista's targeted glue sticks the landing in AML test, supporting push into the clinic - Fierce Biotech
Kazia Therapeutics Announces Collaboration and In-Licensing Agreement for First-in-Class PD-L1 Protein Degrader Program - Yahoo Finance
Prelude calls it curtains on lead SMARCA2 cancer asset - Fierce Biotech
Foghorn Therapeutics shares progress on three protein degrader programs - bioworld.com
Innocare’s VAV1 degrader ICP-538 cleared for clinic in China - bioworld.com
Larkspur Biosciences Begins Dosing in Clinical Study of LRK-4189, a First-in-Class Targeted Protein Degrader - GlobeNewswire
NiKang Therapeutics Presents Discovery of NKT5097, a First-in-Class, Highly Potent and Selective, Orally Bioavailable CDK2/4 Dual Degrader for Cancer Therapy at SABCS 2025 - Business Wire
FDA Approves Imlunestrant for ER+ and HER2-Negative Breast Cancer - AJMC
Monte Rosa: H1 2026 NEK7 Protein Degrader MRT-8102 Data Could Be Added POC - Seeking Alpha
Arvinas to Present Clinical Data for ARV-102, a PROTAC LRRK2 Degrader, at the 2025 International Congress of Parkinson’s Disease and Movement Disorders® - Yahoo Finance
Neither Arvinas nor Pfizer now wants vepdegestrant | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline
ICR Centre for Protein Degradation and NEOsphere Biotechnologies announce research collaboration to discover new molecular glue degrader therapeutics - The Institute of Cancer Research
30 Imlunestrant, an Oral Selective Estrogen Receptor Degrader, as Monotherapy and Combined With Abemaciclib, for Patients with ER+, HER2– Advanced Breast Cancer, Pretreated With Endocrine Therapy: Results of the Phase 3 EMBER-3 Trial - CancerNetwork
Kymera: Expanding Degrader Pipeline and Early Clinical Validation Support Buy Rating and Favorable Risk-Reward - TipRanks
Foghorn Therapeutics CEO Talks Lilly-Partnered SMARCA2 Phase 1 and New Degrader Targets at Conference - MarketBeat
Orum Therapeutics Appoints Chad May as Chief Scientific Officer to Drive Degrader-Antibody Conjugate Innovation and Programs - Business Wire
Foreign Language Equivalents
Foreign Language Equivalents of 'degrader'
Language Equivalent   Language Equivalent
French    Spanish
Misspellings - Typos
dgerader,   egrader,   degrsder,   dgrader,   edgrader,   degraer,   degader,   degrador,   degradr,   deegrader,   segrader,   degrafer,   degrrader,   degradet,   degraderr,   defrader,   degraser,   degradee,   deggrader,   derader,   degradre,   ddegrader,   degrdaer,   dehrader,   dergader,   degraader,   drgrader,   fegrader,   degrder,   degeader,   degrade,   degradder,   degradrr,   degraedr,   degtader,   degarder,   degradeer,   degradwr,   dwgrader
Words Starting with Letter - 'A'
a a battery a billion
a bit a bit much a capella singing
a cappella singing a couple of a few
a fortiori a good deal a great deal
a horizon a hundred a hundred and one
a hundred thousand a hundred times a kempis
a la carte a la mode a level
a little a lot a million
Go to Page 1              Go to Page 2 »   
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z